These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11263864)

  • 1. Diazenes as modificators of drug-resistance in tumor cells.
    Osmak M; Bordukalo T; Ristov AA; Jernej B; Kosmrlj J; Polanc S
    Neoplasma; 2000; 47(6):390-5. PubMed ID: 11263864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diazenes: modificators of tumor cell resistance to cisplatin.
    Osmak M; Bordukalo T; Kosmrlj J; Kvajo M; Marijanović Z; Eljuga D; Polanc S
    Neoplasma; 1999; 46(4):201-6. PubMed ID: 10613598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects of diazenes on tumor cells in vitro.
    Moskatelo D; Benjak A; Laketa V; Polanc S; Kosmrlj J; Osmak M
    Chemotherapy; 2002 Mar; 48(1):36-41. PubMed ID: 11901255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazene JK-279: potential anticancer drug.
    Osmak M; Bordukalo T; Jernej B; Kosmrlj J; Polanc S
    Anticancer Drugs; 1999 Oct; 10(9):853-9. PubMed ID: 10587296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diazenecarboxamide UP-91, a potential anticancer agent, acts by reducing cellular glutathione content.
    Moskatelo D; Polanc S; Kosmrlj J; Vuković L; Osmak M
    Pharmacol Toxicol; 2002 Nov; 91(5):258-63. PubMed ID: 12570033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha(v)beta(3) Integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species.
    Brozovic A; Majhen D; Roje V; Mikac N; Jakopec S; Fritz G; Osmak M; Ambriovic-Ristov A
    Mol Pharmacol; 2008 Jul; 74(1):298-306. PubMed ID: 18441044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structurally similar diazenes exhibit significantly different biological activity.
    Jakopec S; Dubravcic K; Brozovic A; Polanc S; Osmak M
    Cell Biol Toxicol; 2006 Jan; 22(1):61-71. PubMed ID: 16463020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin.
    Osmak M; Eljuga D
    Res Exp Med (Berl); 1993; 193(6):389-96. PubMed ID: 8122044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methyl 2-(2-chloroethylaminocarbonyl)diazenecarboxylate SB-166 inhibits the growth of different tumour cell lines, including drug-resistant sublines.
    Cimbora T; Bombek S; Polanc S; Osmak M
    Toxicol In Vitro; 2003 Apr; 17(2):159-64. PubMed ID: 12650669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.
    Kim HS; Lee TB; Choi CH
    Biochem Biophys Res Commun; 2001 Feb; 281(1):109-14. PubMed ID: 11178967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
    Abraham SA; McKenzie C; Masin D; Ng R; Harasym TO; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Jan; 10(2):728-38. PubMed ID: 14760096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro chemosensitivity test for seven undifferentiated thyroid carcinoma cell lines using MTT assay].
    Osawa Y; Yoshida A; Asaga T; Kawahara S; Yanoma S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):471-6. PubMed ID: 8678500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines.
    Iida K; Nobori T; Matsumine A; Isaka A; Seto M; Shiraishi T; Uchida A
    Oncol Rep; 2003; 10(6):1961-5. PubMed ID: 14534726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro.
    Brezicka T; Einbeigi Z
    Tumour Biol; 2001; 22(2):97-103. PubMed ID: 11125282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): cross-resistance patterns.
    Beketić-Oresković L; Osmak M
    Neoplasma; 1994; 41(3):171-6. PubMed ID: 7935986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemosensitivity test for thyroid cancer by in vitro MTT assay].
    Sasaki F; Ishimura H; Takada N; Uchino J
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1777-81. PubMed ID: 7574809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
    Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
    Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.